MedAvante Names Leading Expert to Head Neurocognition Therapeutic Area
HAMILTON, N.J., Jan. 10, 2011 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system (CNS) disorders, announced the appointment of Christopher Randolph, PhD, ABPP-CN, to the new position of Vice President, Neurocognition. Dr. Randolph will lead a growing team of clinical and training experts and experienced, calibrated clinicians focusing on Alzheimer's disease (AD), mild cognitive impairment (MCI) and other neurocognitive disorders.
"MedAvante has made a serious commitment to helping drug developers in this vital therapeutic category reduce their risk of failure due to inconclusive trial results," said Paul M. Gilbert, Chief Executive Officer of MedAvante. "Chris Randolph is a highly accomplished, widely recognized expert in Alzheimer's disease clinical trials, and he brings with him a wealth of domain expertise as well as a highly successful study track record."
"Having Chris Randolph join our senior scientific leadership team ideally complements MedAvante's science-driven methodologies that are bringing about a paradigm shift in the way CNS clinical trials are conducted," said Gilbert.
Dr. Randolph is the author of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a brief neurocognitive battery used widely around the world. He has consulted on test development for over 20 years, including the revisions of the Wechsler intelligence and memory scales. His extensive experience in CNS clinical trials includes work as an investigator and consultant, as well as creating and supervising rater training programs for a large number of Phase 2 and Phase 3 multinational studies in AD, schizophrenia, stroke, hepatic encephalopathy, and traumatic brain injury.
"The landscape of CNS clinical trials has changed substantially over the last 10-15 years, particularly in Alzheimer's disease," said Dr. Randolph. "Today's em